MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
3.900
-2.780
-41.62%
After Hours: 3.710 -0.19 -4.87% 16:51 12/18 EST
OPEN
4.600
PREV CLOSE
6.68
HIGH
4.900
LOW
3.620
VOLUME
2.78M
TURNOVER
--
52 WEEK HIGH
27.50
52 WEEK LOW
2.738
MARKET CAP
8.84M
P/E (TTM)
-0.1114
1D
5D
1M
3M
1Y
5Y
1D
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
NASDAQ · 8h ago
Why MillerKnoll Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 12h ago
Here’s Why Penny Stock Processa Pharmaceuticals Stock (PCSA) Is Exploding Today
TipRanks · 1d ago
Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?
Benzinga · 1d ago
Processa Pharma Stock Jumps on Positive Data for Breast-Cancer Treatment
Dow Jones · 1d ago
NASDAQ TRADE HALT CONTINUES <PCSA.O> VOLATILITY TRADING PAUSE AT 11:01 AM
Reuters · 1d ago
Processa Pharma Provides Clinical Update On Ongoing Phase 2 Study Of NGC-Cap, Combination Treatment Of PCS6422 And Capecitabine, In Patients With Advanced Or Metastatic Breast Cancer
Benzinga · 1d ago
Processa Pharmaceuticals provides update on Phase 2 NGS-Cap
TipRanks · 1d ago
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.